PL - Awiqli - Insulin - Basal.xlsx
XLSX spreadsheet 45 KB Posted
- Solicitation number
- HT9402-26-Q-9402
- Issued by
-
Defense Health Agency
About this file
This is a pricing template and formulary submission document for basal insulin products under the Department of War's Uniform Formulary (UF) Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for the November 2026 Pharmacy and Therapeutics Committee meeting. The document serves as the price list appendix that manufacturers must complete and submit as part of their response to RFQ HT9402-26-Q-9402.
The template includes ten drug appendices for newly approved basal insulin products, with each appendix requiring manufacturers to submit pricing for two formulary scenarios: Uniform Formulary After Step Therapy and Non-Formulary After Step Therapy. For the BPA portion, manufacturers must provide price per NDC package size and price per unit for Military Treatment Facility and Mail Order channels. For the ADP sections, manufacturers submit either non-FAMP pricing with additional refund percentages and Federal Ceiling Price information, or WAC (Wholesale Acquisition Cost) discount percentages for TRICARE retail refund scenarios. The document specifies that quotes are due by August 27, 2026, and notes that Prior Authorization may apply to these agents. Manufacturers must also submit a Quote Review Checklist and fully executed signature pages, and pens and vials of the same product may be considered as one product if pricing per unit is similar. Price per unit must remain consistent across all package sizes within each dispensing venue.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| PL - Lipfendra - Antilipidemics-1 - PCSK-9.xlsx | XLSX spreadsheet | |
| PL - Trutakna - Nephrology Ag Misc - NA.xlsx | XLSX spreadsheet | |
| RFQ HT9402-26-Q-9402 NAD.pdf | ||
| PL - Cavhanza - Leukemia N Lymphoma Ag - BCR-ABL TKIs.xlsx | XLSX spreadsheet | |
| Formulary Placement of FDA NADs.pdf | ||
| Price Appendix FAQ NAD.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Some manufacturers have both an autoinjector/pen and a vial. The Committee may consider pens and vials as one product in determining the formulary placement if the pricing is similar per unit. Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Some manufacturers have both an autoinjector/pen and a vial. The Committee may consider pens and vials as one product in determining the formulary placement if the pricing is similar per unit. Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Some manufacturers have both an autoinjector/pen and a vial. The Committee may consider pens and vials as one product in determining the formulary placement if the pricing is similar per unit. Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | August 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .